BCMA Targeted Therapies Market Advances Through Innovative Multiple Myeloma Treatment Strategies
BCMA as a Transformative Target in Multiple Myeloma B-cell maturation antigen (BCMA), also known as TNFRSF17, has emerged as an important therapeutic target in multiple myeloma because of its predominant expression on malignant plasma cells and mature B-lineage cells. BCMA contributes to